Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H12O4 |
| Molecular Weight | 256.2534 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC2=C(C(=O)C[C@H](O2)C3=CC=CC=C3)C(O)=C1
InChI
InChIKey=URFCJEUYXNAHFI-ZDUSSCGKSA-N
InChI=1S/C15H12O4/c16-10-6-11(17)15-12(18)8-13(19-14(15)7-10)9-4-2-1-3-5-9/h1-7,13,16-17H,8H2/t13-/m0/s1
| Molecular Formula | C15H12O4 |
| Molecular Weight | 256.2534 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Pinocembrin (5,7-dihydroxyflavanone) is one of the primary flavonoids isolated from the variety of plants, mainly from Pinus heartwood, Eucalyptus, Populus, Euphorbia, and Sparattosperma leucanthum. Pinocembrin is a major flavonoid molecule incorporated as multifunctional in the pharmaceutical industry. Its vast range of pharmacological activities has been well researched including antimicrobial, anti-inflammatory, antioxidant, and anticancer activities. In addition, pinocembrin can be used as neuroprotective against cerebral ischemic injury with a wide therapeutic time window, which may be attributed to its antiexcitotoxic effects.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25907027 |
44.9 µM [IC50] | ||
Target ID: CHEMBL5669 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23725831 |
2.58 µM [IC50] | ||
Target ID: CHEMBL1978 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21802698 |
0.9 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
277 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24733513 |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PINOCEMBRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.46 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25814318 |
150 mg single, intravenous dose: 150 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PINOCEMBRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.82 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25814318 |
60 mg 2 times / day multiple, intravenous dose: 60 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
PINOCEMBRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.22 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25814318 |
80 mg single, intravenous dose: 80 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PINOCEMBRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
0.28 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25814318 |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PINOCEMBRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10338.1 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24733513 |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PINOCEMBRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
89.34 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25814318 |
150 mg single, intravenous dose: 150 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PINOCEMBRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
30.82 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25814318 |
60 mg 2 times / day multiple, intravenous dose: 60 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
PINOCEMBRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
44 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25814318 |
80 mg single, intravenous dose: 80 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PINOCEMBRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
10.34 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25814318 |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PINOCEMBRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
47.4 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24733513 |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PINOCEMBRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
54.5 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25814318 |
150 mg single, intravenous dose: 150 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PINOCEMBRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
50.3 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25814318 |
60 mg 2 times / day multiple, intravenous dose: 60 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
PINOCEMBRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
55.7 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25814318 |
80 mg single, intravenous dose: 80 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PINOCEMBRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
47.4 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25814318 |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PINOCEMBRIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Phytochemical and antimicrobial investigations of stilbenoids and flavonoids isolated from three species of Combretaceae. | 2012-07 |
|
| NF-kappaB-activated tissue transglutaminase is involved in ethanol-induced hepatic injury and the possible role of propolis in preventing fibrogenesis. | 2008-04-18 |
|
| Combinatorial biosynthesis of flavones and flavonols in Escherichia coli. | 2006-06 |
|
| Efficient production of (2S)-flavanones by Escherichia coli containing an artificial biosynthetic gene cluster. | 2005-09 |
|
| The inhibition of superoxide anion generation by neutrophils from Viscum articulactum. | 2004-07 |
|
| Enzymatic characterization and interspecies difference of phenol sulfotransferases, ST1A forms. | 2001-03 |
|
| Cytotoxic activity of low molecular weight polyphenols against human oral tumor cell lines. | 2000-08-23 |
|
| Two antimicrobial flavanones from the leaves of Glycyrrhiza glabra. | 1988-10 |
|
| [On the antimicrobial activity of propolis and propolis constituents (author's transl)]. | 1979 |
|
| [Effect of propolis and pinocembrin on fungi]. | 1977-11 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25814318
A double-blind, placebo-controlled, randomized study was carried out in 58 healthy subjects. Single ascending doses of pinocembrin (20-150 mg) were evaluated in 5 cohorts. Multi-dose was studied at pinocembrin 60 mg. Pinocembrin displayed linear plasma pharmacokinetics over the dose range, 20-150 mg and was well tolerated up to 120 mg day(-1) when administered intravenously to healthy adults.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17074538
Pinocembrin (5 approximately 100 uM) induced relaxation in rat aortic rings pre-contracted with norepinephrine (NE, 1 uM) or KCl (60 mM), with pEC(50) value 4.37+/-0.02 and 4.52+/-0.04. Pretreatment with pinocembrin (30 or 50 uM) also inhibited contractile responses to NE and KCl.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:51:53 GMT 2025
by
admin
on
Mon Mar 31 22:51:53 GMT 2025
|
| Record UNII |
8T7C8CH791
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
1394 (Number of products:104)
Created by
admin on Mon Mar 31 22:51:53 GMT 2025 , Edited by admin on Mon Mar 31 22:51:53 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
279005
Created by
admin on Mon Mar 31 22:51:53 GMT 2025 , Edited by admin on Mon Mar 31 22:51:53 GMT 2025
|
PRIMARY | |||
|
DTXSID3075412
Created by
admin on Mon Mar 31 22:51:53 GMT 2025 , Edited by admin on Mon Mar 31 22:51:53 GMT 2025
|
PRIMARY | |||
|
68071
Created by
admin on Mon Mar 31 22:51:53 GMT 2025 , Edited by admin on Mon Mar 31 22:51:53 GMT 2025
|
PRIMARY | |||
|
28157
Created by
admin on Mon Mar 31 22:51:53 GMT 2025 , Edited by admin on Mon Mar 31 22:51:53 GMT 2025
|
PRIMARY | |||
|
Pinocembrin
Created by
admin on Mon Mar 31 22:51:53 GMT 2025 , Edited by admin on Mon Mar 31 22:51:53 GMT 2025
|
PRIMARY | |||
|
480-39-7
Created by
admin on Mon Mar 31 22:51:53 GMT 2025 , Edited by admin on Mon Mar 31 22:51:53 GMT 2025
|
PRIMARY | |||
|
8T7C8CH791
Created by
admin on Mon Mar 31 22:51:53 GMT 2025 , Edited by admin on Mon Mar 31 22:51:53 GMT 2025
|
PRIMARY |